RecruitingPhase 2NCT05483400

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors: TIRACAN

Sponsor

University Medical Center Groningen

Enrollment

97 participants

Start Date

Oct 18, 2023

Study Type

INTERVENTIONAL

Conditions

Melanoma Head and Neck Neoplasms MSI-H Cancer

Summary

In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two immunotherapy drugs — atezolizumab and tiragolumab — in people with various solid tumors. These drugs work together to help the immune system better recognize and attack cancer cells. The study is a 'basket trial,' meaning it includes multiple cancer types. **You may be eligible if...** - You are 18 or older - You have a solid tumor that can be safely biopsied - You have measurable disease on scans - Your general health and organ function are adequate (ECOG 0–1) - Your life expectancy is at least 12 weeks - You are willing to participate in an additional imaging study using a special CD8 scan **You may NOT be eligible if...** - Your organ function (liver, kidneys, blood counts) does not meet the required thresholds - Your tumor cannot be safely biopsied - You do not have measurable disease - Your performance status is too poor (ECOG 2 or higher) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.